Faricimab (used for wet AMD and diabetic macular edema) has a dual mechanism of action targeting which two pathways?

• A VEGF-A and PDGF-B
• B VEGF-A and complement pathway (C3)
• C VEGF-A and angiopoietin-2 (Ang-2) ✓
• D VEGF-A and integrin αvβ3

Explanation

Faricimab is a bispecific antibody that simultaneously inhibits VEGF-A (reducing angiogenesis) and angiopoietin-2 (Ang-2). Ang-2, by competing with Ang-1 at the Tie-2 receptor on vascular endothelium, promotes vascular destabilisation and leakage. By blocking both pathways together, faricimab provides superior vascular stabilisation and potentially longer treatment intervals. PDGF-B targeting (with rinucumab) was investigated but not approved. Complement pathway agents (e.g., pegcetacoplan) target geographic atrophy, not wet AMD.

Reference: Khurana Comprehensive Ophthalmology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.